ORIC Q2 2026: Cash Runway Extended to H2 2028 as Rinzimetostat Phase 3 Launches
ORIC sits 46% above its 52-week low of $7.23.
Summary
ORIC reported Q2 2026 results with a cash runway into H2 2028, initiated a Phase 3 trial for rinzimetostat, and disclosed insider trading plan adoptions.
Key Events · Earnings and Guidance · ORIC
-
Cash Runway Extended to H2 2028
Cash, equivalents, and investments totaled $387.6M at June 30, 2026, funding operations into the second half of 2028, beyond expected key clinical milestones.
-
Rinzimetostat Phase 3 Trial Initiated
The Himalayas-1 global Phase 3 registrational trial for rinzimetostat in combination with darolutamide began in post-abiraterone mCRPC patients, with Bayer supplying darolutamide at no cost.
-
R&D Spending Driven by Lead Program
Research and development expenses rose to $67.7M in H1 2026 from $55.2M a year earlier, primarily due to increased external costs for rinzimetostat's advancement.
-
Insider Trading Plans Adopted
CFO Dominic Piscitelli adopted a 10b5-1 plan for up to 200,600 shares and Director Mardi Dier adopted a plan for up to 114,383 shares, with sales beginning in August and September 2026, respectively.
Analysis · ORIC · Life Sciences
With a cash position of $387.6M, ORIC can fund operations into the second half of 2028, comfortably past key clinical readouts. The quarter marked the start of the Himalayas-1 global Phase 3 trial for rinzimetostat in prostate cancer, backed by a Bayer supply agreement. R&D spending climbed to $67.7M in H1 2026, driven by the lead program's advancement. The CFO and a director adopted 10b5-1 trading plans, signaling planned future sales but not immediate dilution. The net loss widened to $77.3M, in line with a pre-revenue biotech scaling its pivotal trials.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ORIC was trading at $10.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $7.23 to $14.93. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.